IP Library Granted Patent US 8,008,302
Granted Patent B2
US 8,008,302 · App. 11/572,761 · Granted Aug 30, 2011

N-hydroxyamide derivatives and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,008,302
App. No.
11/572,761
Granted
Aug 30, 2011
Kind
B2
Abstract

The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

Claims (259)

1. A N-hydroxyamide according to Formula (I),

wherein:

A is N;

R 1 is selected from C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 3 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl;

R 4 , R 5 , R 6 and R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

wherein R 1 -R 7 may be substituted by from 1 to 5 substituents selected from the group consisting of C 1 -C 6 -alkyl, amino, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, and nitro;

Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration selected from “S” and “R” and wherein chiral center (3) has a “S” configuration as well as pharmaceutically acceptable salts thereof.

2. A N-hydroxyamide according to claim 1 having a Formula (Ia):

wherein A is N;

R 1 is selected from C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 3 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl;

R 4 , R 5 , R 6 and R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration selected from “S” and “R” and wherein chiral center (3) has a “S” configuration as well as pharmaceutically acceptable salts thereof.

3. A N-hydroxyamide according to claim 1 wherein R 1 is selected from aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, and benzofuranyl.

4. A N-hydroxyamide according to claim 1 wherein R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl.

5. A N-hydroxyamide according to claim 1 wherein R 2 is aryl.

6. A N-hydroxyamide according to claim 1 wherein R 2 is optionally substituted C 3 -C 8 -cycloalkyl.

7. A N-hydroxyamide according to claim 1 wherein R 3 is H.

8. A N-hydroxyamide according to claim 1 wherein R 4 , R 5 and R 7 are H.

9. A N-hydroxyamide according to claim 1 wherein R 6 is selected from H and C 1 -C 6 alkyl.

10. A N-hydroxyamide according to claim 1 wherein R 5 and R 6 are H and R 4 and R 7 can form together a —CH 2 — linkage.

11. A N-hydroxyamide according to claim 1 wherein the configuration of the chiral carbons is (2S), (3S).

12. A N-hydroxyamide according to claim 1 wherein the configuration of the chiral carbons is (2R), (3S).

13. A N-hydroxyamide according to claim 1 wherein R 1 is aryl; R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and C 3 -C 8 -cycloalkyl; R 3 , R 4 , R 5 and R 7 are H; R 6 is selected from H and methyl; A is N; and n is an integer selected from 1, 2 and 3.

14. A N-hydroxyamide according to claim 1 wherein R 1 is selected from aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, and benzofuranyl; R 2 is aryl; R 3 , R 4 , R 5 and R 7 are H; R 6 is selected from H and methyl; A is N; and n is an integer selected from 1, 2 and 3.

15. A N-hydroxyamide compound selected from the group consisting of:

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[4-(3-phenyl-1,2,4-thiadiazol-5-yl)-1-piperazinyl]carbonyl}hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-(2-pyridinyl)piperazinyl]carbonyl}hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2S)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-pyrimidin-2-ylpiperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2S)-2-methyl-4-(4-methylpyridin-2-yl)piperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-3-{[(2R)-4-(2-fluoro-5-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-N,2-dihydroxy-3-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(4-chloro-2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(5-chloropyridin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-3-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-3-{[(1S,4S)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-N,2-dihydroxy-5-methyl-3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]hexanamide;

(2R,3S)-N,2-dihydroxy-5-methyl-3-({4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)hexanamide;

(2R,3S)-3-{[4-(2-fluorophenyl)piperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-N,2-dihydroxy-5-methyl-3-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}carbonyl)hexanamide;

(2S,3S)-3-{[(2R)-4-biphenyl-4-yl-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2S)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(3-chlorophenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-N,2-dihydroxy-5-methyl-3-{[4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-(5-phenylpyridin-2-yl)piperazin-1-yl]carbonyl}hexanamide;

3-[(4-biphenyl-4-ylpiperazin-1-yl)carbonyl]-3,4-dideoxy-1-(hydroxyamino)-5-O-(phenylmethyl)-L-threo-pentose;

(2R,3S)-N,2-dihydroxy-5-methyl-3-{[4-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-3-{[4-(2-fluorophenyl)piperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-N,2-dihydroxy-5-methyl-3-({4-[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]piperazin-1-yl}carbonyl)hexanamide;

(2R,3S)-3-{[(2R)-4-(5-chloropyridin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-3-{[4-(5-chloropyridin-2-yl)piperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2R,3S)-3-{[4-(5-bromopyridin-2-yl)piperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(4-chlorophenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-({(2R)-2-methyl-4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)hexanamide;

(2R,3S)-3-benzyl-N,2-dihydroxy-4-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}butanamide;

(2S,3S)-3-benzyl-N,2-dihydroxy-4-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-4-oxobutanamide;

(2R,3S)-N,2-dihydroxy-3-methyl-4-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}butanamide;

(2S)-N,2-dihydroxy-3-methyl-4-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-4-oxobutanamide;

(2S,3S)-3-{[(2R)-4-(4′-fluorobiphenyl-4-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(4-ethoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(3,4-dimethoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(methylsulfonyl)phenyl]piperazin-1-yl}carbonyl)hexanamide;

(2S,3S)-N,2-dihydroxy-3-{[(2R)-4-(6-methoxy-2-naphthyl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanamide;

(2S,3S)-3-({(2R)-4-[4-(1-benzofuran-3-yl)phenyl]-2-methylpiperazin-1-yl}carbonyl)-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-(4-propoxyphenyl)piperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)hexanamide;

(2S,3S)-3-{[(2R)-4-(4-tert-butylphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-(4-propylphenyl)piperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-3-(cyclopentylmethyl)-N,2-dihydroxy-4-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-4-oxobutanamide;

(2S,3S)-3-{[(2R)-4-(2,3-dihydro-1-benzofuran-5-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(1,3-benzodioxol-5-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-3-{[(2R)-4-(4-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-[((2R)-2-methyl-4-{4-[(trifluoromethyl)sulfonyl]phenyl}piperazin-1-yl)carbonyl]hexanamide;

(2S,3S)-N,2-dihydroxy-3-{[(2R)-4-(4′-methoxybiphenyl-4-yl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(4-cyclohexylphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(1-benzofuran-5-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(3-fluoro-4-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(3-fluoro-4-isopropoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-3-({(2R)-4-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpiperazin-1-yl}carbonyl)-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-quinolin-3-ylpiperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-(4-methylphenyl)piperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-3-{[(2R)-4-(5-chloro-2-thienyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-3-{[(2R)-4-(3-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanamide;

(2S,3S)-3-{[(2R)-4-(4′-bromobiphenyl-4-yl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl}carbonyl)hexanamide;

(2S,3S)-3-{[(2R)-4-(4-tert-butoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-3-{[(2R)-4-(4-isopropoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-{[(2R)-2-methyl-4-quinolin-6-ylpiperazin-1-yl]carbonyl}hexanamide;

(2S,3S)-3-({(2R)-4-[3,5-bis(trifluoromethyl)phenyl]-2-methylpiperazin-1-yl}carbonyl)-N,2-dihydroxy-5-methylhexanamide;

(2S,3S)-N,2-dihydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(1,3-oxazol-5-yl)phenyl]piperazin-1-yl}carbonyl)hexanamide; and

(2S,3S)-3-({(2R)-4-[4-(dimethylamino)phenyl]-2-methylpiperazin-1-yl}carbonyl)-N,2-dihydroxy-5-methylhexanamide.

16. A pharmaceutical composition comprising at least one N-hydroxyamide according to claim 1 , and a pharmaceutically acceptable carrier, diluent or excipient thereof.

17. A process for the preparation of a N-hydroxyamide, according to claim 1 , comprising reacting a compound of Formula (IV) with a derivative H 2 N—O—R 8 :

wherein A, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and n are as defined in claim 1 and R 8 is selected from H and a protective group selected from t-butyl, benzyl, trialkylsilyl, tetrahydropyranyl.

18. A process for the preparation of a N-hydroxyamide, according to claim 1 , comprising reacting a compound of Formula (V) with a derivative H 2 N—O—R 8 :

wherein A, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and n are as defined in claim 1 and R 8 is selected from H and a protective group.

19. A process according to claims 17 , wherein R 8 is a protective group and the process further comprises deprotecting the compound of formula (I) by removing the protective group.

20. A process for the preparation of a N-hydroxyamide, according to claim 1 , comprising reacting a compound of Formula (II) with an amine of Formula (III) to form a compound of Formula (IV), optionally in presence of a coupling agent selected from DIC, EDC, TBTU, DCC, HATU, PyBOP®, Isobutyl chloroformate and 1-methyl-2-chloropyridinium iodide; and reacting the compound of formula (IV) with hydroxylamine or a protected hydroxylamine and, if protected hydroxylamine, removing the protecting group to form a compound of formula (I)

wherein A, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and n are as defined in claim 1 ; G is a group selected from OH and Cl.

21. A compound according to Formula (IV):

wherein A is N;

R 1 is selected from C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 4 , R 5 , R 6 and R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

wherein R 1 , R 2 , R 4 , R 5 , R 6 and R 7 may be substituted by from 1 to 5 substituents selected from the group consisting of C i -C 6 -alkyl, amino, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, and nitro;

Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration selected from “S” and “R” and wherein chiral center (3) has a “S” configuration as well as pharmaceutically acceptable salts thereof.

22. A compound selected from the group consisting of:

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[4-(3-phenyl-1,2,4-thiadiazol-5-yl)-1-piperazinyl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-[(1S)-3-methyl-1-({(2R)-2-methyl-4-[4-(trifluoromethyl) pyridin-2-yl]piperazin-1-yl}carbonyl)butyl]-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2R)-2-methyl-4-(2-pyridinyl)piperazinyl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2S)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-5-((1S)-4-(4-ethoxyphenyl)-1-{[(2R)-2-methyl-4-(2-pyridinyl) piperazinyl]carbonyl}butyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-4-(4-ethoxyphenyl)-1-{[(2S)-2-methyl-4-(2-pyridinyl)piperazinyl]carbonyl}butyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-4-(4-ethoxyphenyl)-1-{[(2R)-2-methyl-4-(2-pyrimidinyl)piperazinyl]carbonyl}butyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-4-(4-ethoxyphenyl)-1-{[(2R)-4-(2-fluorophenyl)-2-methyl piperazinyl]carbonyl}butyl)-2,2-dimethyl-1,3 -dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2R)-2-methyl-4-pyrimidin-2-ylpiperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2S)-2-methyl-4-(4-methylpyridin-2-yl) piperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-5-[(1S)-1-({(2R)-4-[2-fluoro-5-(methyloxy)phenyl]-2-methylpiperazin-1-yl}carbonyl)-3-methylbutyl]-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-5-((1S)-1-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[2R)-4-(4-chloro-2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(5-chloropyridin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-5-((1S)-1-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-5-((1S)-1-{[(1S,4S)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-2,2-dimethyl-5-{(1S)-3-methyl-1-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]butyl}-1,3-dioxolan-4-one;

(5R)-2,2-dimethyl-5-[(1S)-3-methyl-1-({4-[4-(trifluoromethy)phenyl]piperazin-1-yl}carbonyl)butyl]-1,3-dioxolan-4-one;

(5R)-5-((1S)-1-{[4-(2-fluorophenyl)piperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-2,2-dimethyl-5-{(1S)-3-methyl-1-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]butyl}-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-{(1S)-3-methyl-1-[((2R)-2-methyl-4-{4-[(trifluoromethyl)oxy]phenyl}piperazin-1-yl)carbonyl]butyl}-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-biphenyl-4-yl-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2S)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(3-chlorophenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-2,2-dimethyl-5-((1S)-3-methyl-1-{[4-(5-phenyl-1,2,4-oxadiazol-3-yl)-1-piperazinyl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2R)-2-methyl-4-(5-phenylpyridin-2-yl)piperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

3-[(4-biphenyl-4-ylpiperazin-1-yl)carbonyl]-3,4-dideoxy-1,2-O-(1-methylethylidene)-5-O-(phenylmethyl)-L-threo-pentonic acid;

(5R)-2,2-dimethyl-5-((1S)-3-methyl-1-{[4-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl) piperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[4-(2-fluorophenyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-2,2-dimethyl-5-[1S)-3-methyl-1-({4-[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]piperazin-1-yl}carbonyl)butyl]-1,3-dioxolan-4-one;

(5R)-5-(1-{[(2R)-4-(5-chloropyridin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methyl butyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-5-((1S)-1-{[4-(5-chloropyridin-2-yl)piperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-5-((1S)-1-{[4-(5-bromopyridin-2-yl)piperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1R)-1-{[(2R)-4-(4-chlorophenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-[(1R)-3-methyl-1-({(2R)-2-methyl-4-[5-(trifluoromethyl) pyridin-2-yl]piperazin-1-yl}carbonyl)butyl]-1,3-dioxolan-4-one;

(5R)-5-((1S)-1-benzyl-2-oxo-2-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}ethyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-benzyl-2-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-2-oxoethyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5R)-2,2-dimethyl-5-((1S)-1-methyl-2-oxo-2-{4- [4-(trifluoromethoxy)phenyl]piperazin-1-yl}ethyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-(1-methyl-2-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-2-oxoethyl)-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(4′-fluorobiphenyl-4-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1R)-1-{[(2R)-4-(4-ethoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(3,4-dimethoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-[3-methyl-1-({(2R)-2-methyl-4-[4-(methylsulfonyl)phenyl]piperazin-1-yl}carbonyl)butyl]-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(6-methoxy-2-naphthyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-[(1S)-1-({(2R)-4-[4-(1-benzofuran-3-yl)phenyl]-2-methylpiperazin-1-yl}carbonyl)-3-methylbutyl]-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2R)-2-methyl-4-(4-propoxyphenyl)piperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-[(1S)-3-methyl-1-({(2R)-2-methyl-4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)butyl]-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(4-tert-butylphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2R)-2-methyl-4-(4-propylphenyl)piperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-(cyclopentylmethyl)-2-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-2-oxoethyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(2,3-dihydro-1-benzofuran-5-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(1,3-benzodioxol-5-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(4-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-{(1S)-3-methyl-1-[((2R)-2-methyl-4-{4-[(trifluoromethyl)sulfonyl]phenyl}piperazin-1-yl)carbonyl]butyl}-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(4′-methoxybiphenyl-4-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-(1-{[(2R)-4-(4-cyclohexylphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(1-benzofuran-5-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-(1-{[(2R)-4-(3-fluoro-4-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(3-fluoro-4-isopropoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-[(1S)-1-({(2R)-4-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpiperazin-1-yl}carbonyl)-3-methylbutyl]-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2R)-2-methyl-4-quinolin-3-ylpiperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[(2R)-2-methyl-4-(4-methylphenyl)piperazin-1-yl]carbonyl}butyl)-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(5-chloro-2-thienyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one;

(5S)-5-((1S)-1-{[(2R)-4-(3-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-3-methylbutyl)-2,2-dimethyl-1,3-dioxolan-4-one.

23. A compound according to Formula (V):

wherein A is selected from —C(B)—and N;

R 1 is selected from C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 4 , R 5 , R 6 and R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

wherein R 1 , R 2 , R 4 , R 5 , R 6 and R 7 may be substituted by from 1to 5substituents selected from the group consisting of C 1 -C 6 -alkyl, amino, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, and nitro;

Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration selected from “S” and “R” and wherein chiral center (3) has a “S” configuration as well as pharmaceutically acceptable salts thereof.

24. A compound selected from the group consisting of:

(2S,3S)-2-hydroxy-5-methyl-3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2R)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2S)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2R)-2-methyl-4-pyrimidin-2-ylpiperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2S)-2-methyl-4-(4-methylpyridin-2-yl)piperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-3-{[(2R)-4-(2-fluoro-5-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-2-hydroxy-3-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(4-chloro-2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(5-chloropyridin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-3-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-2-hydroxy-5-methyl-3-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]hexanoic acid;

(2R,3S)-2-hydroxy-5-methyl-3-({4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)hexanoic acid;

(2R,3S)-3-{[4-(2-fluorophenyl)piperazin 1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-2-hydroxy-5-methyl-3-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}carbonyl)hexanoic acid;

(2S,3S)-3-{[(2R)-4-biphenyl-4-yl-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2S)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(3-chlorophenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-2-hydroxy-5-methyl-3-{[4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2R)-2-methyl-4-(5-phenylpyridin-2-yl)piperazin-1-yl]carbonyl}hexanoic acid;

5-O-benzyl-3-[(4-biphenyl-4-ylpiperazin-1-yl)carbonyl]-3,4-dideoxy-L-threo-pentonic acid;

(2R,3S)-2-hydroxy-5-methyl-3-{[4-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)piperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-3-{[4-(2-fluorophenyl)piperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-2-hydroxy-5-methyl-3-({4-[5-(2-thienyl)-1,2,4-oxadiazol-3-yl]piperazin-1-ylcarbonyl)hexanoic acid;

(2R,3S)-3-{[(2R)-4-(5-chloropyridin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-3-{[4-(5-chloropyridin-2-yl)piperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2R,3S)-3-{[4-(5-bromopyridin-2-yl)piperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(4-chlorophenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-({(2R)-2-methyl-4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)hexanoic acid;

(2R,3S)-3-benzyl-2-hydroxy-4-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}butanoic acid;

(2S,3S)-3-benzyl-2-hydroxy-4-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-4-oxobutanoic acid;

(2R,3S)-2-hydroxy-3-methyl-4-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}butanoic acid;

(2S)-2-hydroxy-3-methyl-4-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-4-oxobutanoic acid;

(2S,3S)-3-{[(2R)-4-(4′-fluorobiphenyl-4-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(4-ethoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(3,4-dimethoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(methylsulfonyl)phenyl]piperazin-1-yl}carbonyl)hexanoic acid;

(2S,3S)-2-hydroxy-3-{[(2R)-4-(6-methoxy-2-naphthyl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanoic acid;

(2S,3S)-3-({(2R)-4-[4-(1-benzofuran-3-yl)phenyl]-2-methylpiperazin-1-yl}carbonyl)-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2R)-2-methyl-4-(4-propoxyphenyl)piperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-({(2R)-2-methyl-4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)hexanoic acid;

(2S,3S)-3-{[(2R)-4-(4-tert-butylphenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2R)-2-methyl-4-(4-propylphenyl)piperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-3-(cyclopentylmethyl)-2-hydroxy-4-{(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}-4-oxobutanoic acid;

(2S,3S)-3-{[(2R)-4-(2,3-dihydro-1-benzofuran-5-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(1,3-benzodioxol-5-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-2-hydroxy-3-{[(2R)-4-(4-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-[((2R)-2-methyl-4-{4-[(trifluoromethyl)sulfonyl]phenyl}piperazin-1-yl)carbonyl]hexanoic acid;

(2S,3S)-2-hydroxy-3-{[(2R)-4-(4′-methoxybiphenyl-4-yl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(4-cyclohexylphenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(1-benzofuran-5-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(3-fluoro-4-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-{[(2R)-4-(3-fluoro-4-isopropoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-3-({(2R)-4-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methylpiperazin-1-yl}carbonyl)-2-hydroxy-5-methyl hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2R)-2-methyl-4-quinolin-3-ylpiperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-2-hydroxy-5-methyl-3-{[(2R)-2-methyl-4-(4-methylphenyl)piperazin-1-yl]carbonyl}hexanoic acid;

(2S,3S)-3-{[(2R)-4-(5-chloro-2-thienyl)-2-methylpiperazin-1-yl]carbonyl}-2-hydroxy-5-methylhexanoic acid;

(2S,3S)-2-hydroxy-3-{[(2R)-4-(3-methoxyphenyl)-2-methylpiperazin-1-yl]carbonyl}-5-methylhexanoic acid.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2017
From: MERCK SERONO S.A.
To: MERCK PATENT GMBH
Reel/Frame 043839/0219 →
CHANGE OF NAME Recorded Dec 3, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023599/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2007
From: SWINNEN, DOMINIQUE; BOMBRUN, AGNES; GONZALEZ, JEROME; CROSIGNANI, STEFANO; GERBER, PATRICK; JORAND-LEBRUN, CATHERINE
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 019979/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019966/0026 →